{"nctId":"NCT01922102","briefTitle":"Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","startDateStruct":{"date":"2013-09-11","type":"ACTUAL"},"conditions":["Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)"],"count":457,"armGroups":[{"label":"Group I","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab 0.5mg"]},{"label":"Group II","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab 0.5 mg"]},{"label":"Group III","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Verteporfin PDT"]}],"interventions":[{"name":"Ranibizumab 0.5mg","otherNames":["Lucentis"]},{"name":"Ranibizumab 0.5 mg","otherNames":["Lucentis"]},{"name":"Verteporfin PDT","otherNames":["Visudyne"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Visual impairment due to CNV secondary to PM.\n* Best corrected visual acuity in the study eye \\> 24 and \\< 78 ETDRS letters.\n* High myopia (\\> -6D),\n* anterio-posterior elongation \\> 26 mm; posterior changes compatible with the pathologic myopia.\n* Either CNV locations in the study eye: subfoveal, juxtafoveal, extrafoveal.\n\nExclusion Criteria:\n\n* Some preexisting eye disorders or systemic diseases;-Blood pressure \\> 150/90 mmHg\n* Prior focal/grid laser to the macular area -History of treatment with any anti-VEGF or verteporfin PDT in the study eye\n* Intravitreal treatment with corticosteroids or intraocular surgery within last 3 months in the study eye","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3","description":"Best corrected visual acuity (BCVA) was tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) charts testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":"12.65"},{"groupId":"OG001","value":"54.2","spread":"13.01"},{"groupId":"OG002","value":"52.6","spread":"12.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.1","spread":"12.80"},{"groupId":"OG001","value":"63.9","spread":"13.28"},{"groupId":"OG002","value":"57.1","spread":"13.21"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 6","description":"Best corrected visual acuity (BCVA) was tested using the early treatment diabetic retinopathy study (ETDRS) VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.\n\nBetween treatment comparison of 0.5 mg ranibizumab intravitreal injections driven by disease activity re-treatment criteria (Group II) versus 0.5 mg ranibizumab intravitreal injections driven by visual acuity stability criteria (Group I) based on the average BCVA change from Baseline to Month 1 through Month 6.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":"12.65"},{"groupId":"OG001","value":"54.2","spread":"13.01"},{"groupId":"OG002","value":"52.6","spread":"12.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1","spread":"12.77"},{"groupId":"OG001","value":"64.9","spread":"13.14"},{"groupId":"OG002","value":"59.6","spread":"12.99"}]}]}]},{"type":"SECONDARY","title":"The Average Change in BCVA Score From Baseline to Month 1 Through Month 12","description":"Best corrected visual acuity (BCVA) was tested using the ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.\n\nBetween treatment comparison of 0.5 mg ranibizumab intravitreal injections driven by disease activity re-treatment criteria (Group II) versus 0.5 mg ranibizumab intravitreal injections driven by visual acuity stability criteria (Group I) based on the average BCVA change from Baseline to Month 1 through Month 12","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":"12.65"},{"groupId":"OG001","value":"54.2","spread":"13.01"},{"groupId":"OG002","value":"52.6","spread":"12.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.8","spread":"12.82"},{"groupId":"OG001","value":"65.9","spread":"13.26"},{"groupId":"OG002","value":"61.2","spread":"13.10"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Visual Acuity Over Time","description":"Best corrected visual acuity (BCVA) was tested using the ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"9.13"},{"groupId":"OG001","value":"10.8","spread":"10.09"},{"groupId":"OG002","value":"4.5","spread":"9.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":"10.66"},{"groupId":"OG001","value":"12.1","spread":"11.57"},{"groupId":"OG002","value":"9.5","spread":"10.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":"11.50"},{"groupId":"OG001","value":"13.1","spread":"11.46"},{"groupId":"OG002","value":"10.3","spread":"12.69"}]}]}]},{"type":"SECONDARY","title":"Categorized BCVA Changes at Months 3, 6 and 12 Compared With Baseline for the Study Eye","description":"ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"107","spread":null},{"groupId":"OG002","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"121","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"115","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline Over Time in Central Sub-field Thickness (CSFT)","description":"Central sub-field thickness (CSFT) is a variable assessed via Optical Coherence Tomography (OCT). OCT was performed prior to any study drug administration to assess presence of intra, subretinal fluid, or increase of CSFT.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-66.4","spread":"98.68"},{"groupId":"OG001","value":"-71.2","spread":"81.28"},{"groupId":"OG002","value":"-29.1","spread":"75.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-70.7","spread":"73.20"},{"groupId":"OG001","value":"-75.1","spread":"80.90"},{"groupId":"OG002","value":"-59.3","spread":"81.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-79.4","spread":"71.39"},{"groupId":"OG001","value":"-80.8","spread":"85.93"},{"groupId":"OG002","value":"-66.0","spread":"93.60"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With CNV Leakage (Center Involvement) in the Study Eye at Baseline and Month 12","description":"CNV leakage is assessed via fluorescein angiography (center involvement) category: definite, questionable, absent, can't grade, and missing.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"160","spread":null},{"groupId":"OG002","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"129","spread":null},{"groupId":"OG002","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"NEI-VFQ-25 - Change From Baseline to Month 3, 6 and 12","description":"The VFQ-25 consists of 25 vision related questions across 11 vision related subscales, including general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision and peripheral vision, and a general health rating. Items are converted to a 0-100 scale on each subscale and for the composite score where higher scores represents better functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"12.28"},{"groupId":"OG001","value":"6.1","spread":"13.49"},{"groupId":"OG002","value":"1.7","spread":"13.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"13.40"},{"groupId":"OG001","value":"5.6","spread":"15.42"},{"groupId":"OG002","value":"-0.1","spread":"15.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"16.03"},{"groupId":"OG001","value":"4.7","spread":"16.92"},{"groupId":"OG002","value":"1.3","spread":"16.85"}]}]}]},{"type":"SECONDARY","title":"Number of Ranibizumab Injections Received in the Study Eye for the Ranibizumab Groups","description":"To assess treatment pattern with ranibizumab","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"0.53"},{"groupId":"OG001","value":"2.1","spread":"0.84"},{"groupId":"OG002","value":"NA","spread":"NA"},{"groupId":"OG003","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"2.44"},{"groupId":"OG001","value":"3.9","spread":"2.50"},{"groupId":"OG002","value":"3.2","spread":"2.25"},{"groupId":"OG003","value":"3.8","spread":"2.36"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":182},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Conjunctival haemorrhage (Study eye)","Cough","Xerophthalmia (Study eye)"]}}}